Summary & Overview
HCPCS J1270: Doxercalciferol Injection, 1 mcg
HCPCS Level II code J1270 designates the parenteral administration of doxercalciferol, a synthetic vitamin D analog commonly used in the management of secondary hyperparathyroidism, particularly among patients with chronic kidney disease. Nationally, this code matters because injectable vitamin D therapies represent a significant component of specialty medication spend and encounter-level reporting for nephrology and dialysis services.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise outline of what J1270 represents clinically, the typical settings where the drug is administered, and which major payers cover and process claims for this service. The publication also summarizes available benchmarks and policy considerations relevant to administration and billing practices, including reimbursement patterns, documentation expectations, and common billing scenarios.
This summary provides the clinical context and coding identification needed for revenue cycle teams, compliance officers, and clinical program managers to ensure accurate claim submission and mapping to facility or professional services. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J1270 represents an injection of doxercalciferol, dosed per 1 microgram units. This code is used to report administration of the active vitamin D analog doxercalciferol, typically indicated for management of secondary hyperparathyroidism in patients with chronic kidney disease and related conditions.
Service type: Medication injection (parenteral drug administration).
Typical site of service: Hospital outpatient department, physician office, dialysis clinic, or other infusion/administration settings where injectable medications are provided. If specific site-of-service billing is required, facility and place-of-service rules apply.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 62-year-old male with chronic kidney disease stage 5 on hemodialysis who presents for an in-center dialysis session. Laboratory evaluation shows secondary hyperparathyroidism with elevated parathyroid hormone and low-normal serum calcium. The nephrology team orders parenteral vitamin D analog therapy with J1270 (injection, doxercalciferol, 1 mcg) to manage secondary hyperparathyroidism.
In the clinical workflow, nursing reviews orders in the electronic health record, confirms recent labs and calcium levels, verifies no contraindications (hypercalcemia, vitamin D toxicity), and prepares the vial/dose. The medication is administered via intramuscular or intravenous injection per facility protocol during the dialysis session or in the outpatient clinic. Documentation includes indication, lot number, dose administered (number of units of J1270), route, time, patient response, and any immediate adverse reactions. Billing is submitted under HCPCS Level II code J1270 with appropriate modifier(s) to indicate special circumstances (for example, billing for a partial dose, professional service, or an unrelated procedure during the same encounter).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |